BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 25, 2011
 |  BC Week In Review  |  Company News  |  Other News

RegeneRx ophthalmic news

RegeneRx said it will its shift clinical focus to RGN-259 to treat symptomatic dry eye syndrome from RGN-352 after a Phase II trial evaluating RGN-352 to treat acute myocardial infarction was placed on hold by FDA due...

Read the full 185 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >